Table 1 Characteristics of the study population*.
From: The plasma miR-125a, miR-361 and miR-133a are promising novel biomarkers for Late-Onset Hypogonadism
Variable | Discovery and training set | Validation set | ||||
|---|---|---|---|---|---|---|
LOH | control | P | LOH | control | P | |
No. | 10 | 10 | 22 | 22 | ||
Age — yr | 53.4 ± 1.8 | 52.1 ± 1.4 | 0.573 | 53.4 ± 1.4 | 54.3 ± 1.4 | 0.628 |
Height — cm | 164.6 ± 1.2 | 167.9 ± 1.6 | 0.119 | 163.6 ± 2.6 | 167.0 ± 1.1 | 0.233 |
Weight — kg | 72.5 ± 1.9 | 71.8 ± 1.6 | 0.778 | 72.1 ± 1.8 | 73.2 ± 1.3 | 0.629 |
Body-mass index † | 26.8 ± 2.8 | 25.5 ± 2.3 | 0.271 | 27.6 ± 7.1 | 26.3 ± 2.3 | 0.434 |
Waist circumference — cm | 94.5 ± 2.7 | 90.6 ± 2.6 | 0.311 | 93.4 ± 1.9 | 92.1 ± 1.5 | 0.613 |
Smoking status — no./total no. (%) | ||||||
Never smoked | 5(50.0%) | 5(50.0%) | 0.712 | 7(31.8%) | 8(36.4%) | 0.525 |
Current smoker | 5(50.0%) | 4(40.0%) | 15(68.2%) | 12(54.5%) | ||
Former smoker | 0(0%) | 1(10.0%) | 0(0%) | 2(9.1%) | ||
Alcohol intake — no./total no. (%) | ||||||
None | 4(40.0%) | 3(30.0%) | 0.648 | 5(22.7%) | 6(27.3%) | 0.936 |
1–4 days/wk | 2(20.0%) | 2(20.0%) | 6(27.3%) | 7(31.8%) | ||
≥5 days/wk | 4(40.0%) | 5(50.0%) | 11(50.0%) | 9(40.9%) | ||
Body-mass index — no./total no. (%) | ||||||
<24 | 1(10.0%) | 3(30.0%) | 0.328 | 4(18.2%) | 4(18.2%) | 0.766 |
≥24 to <28 | 6(60.0%) | 5(50.0%) | 11(50.0%) | 13(59.1%) | ||
≥28 | 3(30.0%) | 2(20.0%) | 7(31.8%) | 5(22.7%) | ||
AMS Score (low score favorable; range, 17–85) | 31.1 ± 1.9 | 20.2 ± 1.4 | <0.001 | 33.3 ± 1.4 | 20.9 ± 1.0 | <0.001 |
Total Testosterone — nmol/L | 8.9 ± 0.5 | 15.3 ± 0.9 | <0.001 | 8.8 ± 0.3 | 15.5 ± 0.6 | <0.001 |
Sex hormone-binding globulin — nmol/L | 30.0 ± 4.4 | 41.9 ± 3.2 | 0.045 | 32.2 ± 2.7 | 37.9 ± 2.3 | 0.118 |
Free Testosterone — pmol/L | 186.5 ± 8.6 | 272.1 ± 11.6 | <0.001 | 176.9 ± 6.6 | 299.0 ± 15.4 | <0.001 |
luteinizing hormone (IU/L) | 7.0 ± 1.0 | 4.9 ± 0.5 | 0.096 | 6.4 ± 0.6 | 5.3 ± 0.4 | 0.150 |
